Our team will be unavailable from December 25, 2023, to January 1, 2024.
We will resume operations on January 2, 2024. Wishing you a joyful holiday season!

Nephron Employees Receive Raises Thanks To Tax Cuts Law

WEST COLUMBIA, S.C. – Nephron Pharmaceuticals Corporation (Nephron) CEO Lou Kennedy today announced five percent increases for all employees with the exception of commissioned employees.  The raises are a direct result of the Tax Cuts and Jobs Act that was signed into law last week by President Donald Trump.

“We are excited that the Tax Cuts and Jobs Act has given us an opportunity to recognize their hard work and sacrifices with well-deserved raises”, said Lou Kennedy, CEO of Nephron.

Elected officials – including The Honorable Henry McMaster, Governor of South Carolina, U.S. Senator Lindsey Graham, Congressman Joe Wilson, state legislators and local elected officials – joined Kennedy and Nephron employees for today’s announcement celebration at the company’s West Columbia headquarters. Both of South Carolina’s U.S. Senators and six of the state’s seven members of the U.S. House of Representatives voted in favor of the Tax Cuts and Jobs Act.

“I am grateful that the tax cuts House Republicans worked so hard to pass have had an immediate impact in the district,” said Congressman Joe Wilson. “I congratulate Lou and Bill Kennedy, as well as Nephron’s entire team, on today’s announcement, and I wish them continued success.”

Nephron is a manufacturer of respiratory and compounded 503B outsourcing medications that employs 640 people in West Columbia. The company, which launched 34 new products in 2017, recently announced a $12.5 million expansion and expects to add 125 additional employees by June 2018.

Fifty percent of Nephron employees attended South Carolina universities or technical colleges. Nephron founder Bill Kennedy and CEO Lou Kennedy are University of South Carolina graduates and South Carolinians. The company is part of the life sciences industry in the State.  This industry has a total $11.4 billion annual impact on the State economy.

For more information about Nephron, visit http://www.nephronpharm.com.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.